What is NTRB's current stock price?

NTRB (Nutriband Inc.) is currently trading at $3.64 with a market cap of $44.2M.

What sector is Nutriband Inc. in?

Nutriband Inc. (NTRB) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

NTRB Nutriband Inc.

Healthcare

$3.64+4.30%ClosedMarket Cap: $44.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.62

P/S

21.73

EV/EBITDA

-4.91

DCF Value

$-1.56

FCF Yield

-11.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

24.9%

Operating Margin

-408.4%

Net Margin

-404.1%

ROE

-118.3%

ROA

-109.0%

ROIC

-120.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$400.7K	$-968.1K	$—
FY null	$2.0M	$-8.2M	$—
Q3 null	$346.1K	$-3.9M	$—
Q2 null	$622.5K	$-2.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer

SellTue Nov 25

Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer

SellTue Nov 25

Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer

SellTue Nov 25

Goodman Geraldofficer: Chief Financial Officer

SellTue Oct 21

Goodman Geraldofficer: Chief Financial Officer

SellTue Oct 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.96

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Peers